BASILEA PHARMACEUTICA: Successful CHF45.75m equity raise supports our investment case | BUY | CHF91 VS. CHF102 (+90%)
BASILEA PHARMACEUTICA - BUY | CHF91 VS. CHF102 (+90%)Successful CHF45.75m equity raise supports our investment case
One million new shares placed in a private placement
All eyes on Derazantinib as multiple catalysts are expected
Lisavanbulin is Basilea’s wild card for 2021
Cresemba will continue to support Basilea’s top-line growth this year
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.